On May 20, 2024, Maryland’s Prescription Drug Affordability Board (PDAB) voted to initiate cost review and affordability studies for six drugs. In conducting affordability reviews, the Board will consider various factors, including wholesale acquisition costs, price concessions and rebates from manufacturers, costs to health plans, patient access impacts, and the financial implications of therapeutic alternatives. Additionally, the Board may also take into account manufacturers’ research and development costs, marketing expenses, and revenues related to the drug under review. If the Board determines that a drug is unaffordable, it may set upper payment limits (UPL), which are the highest allowable reimbursement rate that purchasers can provide for a prescription drug product. In establishing these limits, the Board will also consider the cost of administering and delivering the drug to consumers, as well as other relevant administrative expenses associated with the drug.
Learn more about Maryland’s PDAB here. Learn more about other state PDABs here.
Last Updated on June 29, 2024 by Aimed Alliance
